These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 27827885)

  • 41. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL; Page DB
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
    Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
    Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.
    Srinivasan P; Wu X; Basu M; Rossi C; Sandler AD
    PLoS Med; 2018 Jan; 15(1):e1002497. PubMed ID: 29377881
    [TBL] [Abstract][Full Text] [Related]  

  • 44. IL2/Anti-IL2 Complex Combined with CTLA-4, But Not PD-1, Blockade Rescues Antitumor NK Cell Function by Regulatory T-cell Modulation.
    Caudana P; Núñez NG; De La Rochere P; Pinto A; Denizeau J; Alonso R; Niborski LL; Lantz O; Sedlik C; Piaggio E
    Cancer Immunol Res; 2019 Mar; 7(3):443-457. PubMed ID: 30651291
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Disruption of CTLA-4 expression on peripheral blood CD8 + T cell enhances anti-tumor efficacy in bladder cancer.
    Zhang W; Shi L; Zhao Z; Du P; Ye X; Li D; Cai Z; Han J; Cai J
    Cancer Chemother Pharmacol; 2019 May; 83(5):911-920. PubMed ID: 30848330
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The emerging role of immune checkpoint based approaches in AML and MDS.
    Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N
    Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300
    [TBL] [Abstract][Full Text] [Related]  

  • 48. OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.
    Linch SN; McNamara MJ; Redmond WL
    Front Oncol; 2015; 5():34. PubMed ID: 25763356
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.
    Chen X; Pan X; Zhang W; Guo H; Cheng S; He Q; Yang B; Ding L
    Acta Pharm Sin B; 2020 May; 10(5):723-733. PubMed ID: 32528824
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.
    Das R; Verma R; Sznol M; Boddupalli CS; Gettinger SN; Kluger H; Callahan M; Wolchok JD; Halaban R; Dhodapkar MV; Dhodapkar KM
    J Immunol; 2015 Feb; 194(3):950-9. PubMed ID: 25539810
    [TBL] [Abstract][Full Text] [Related]  

  • 51. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts.
    Feucht J; Kayser S; Gorodezki D; Hamieh M; Döring M; Blaeschke F; Schlegel P; Bösmüller H; Quintanilla-Fend L; Ebinger M; Lang P; Handgretinger R; Feuchtinger T
    Oncotarget; 2016 Nov; 7(47):76902-76919. PubMed ID: 27708227
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.
    Higuchi T; Flies DB; Marjon NA; Mantia-Smaldone G; Ronner L; Gimotty PA; Adams SF
    Cancer Immunol Res; 2015 Nov; 3(11):1257-68. PubMed ID: 26138335
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer.
    van Hooren L; Sandin LC; Moskalev I; Ellmark P; Dimberg A; Black P; Tötterman TH; Mangsbo SM
    Eur J Immunol; 2017 Feb; 47(2):385-393. PubMed ID: 27873300
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy.
    Chowdhury PS; Chamoto K; Honjo T
    J Intern Med; 2018 Feb; 283(2):110-120. PubMed ID: 29071761
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma.
    Klemen ND; Wang M; Feingold PL; Cooper K; Pavri SN; Han D; Detterbeck FC; Boffa DJ; Khan SA; Olino K; Clune J; Ariyan S; Salem RR; Weiss SA; Kluger HM; Sznol M; Cha C
    J Immunother Cancer; 2019 Jul; 7(1):196. PubMed ID: 31340861
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
    Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
    Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer.
    Niyongere S; Saltos A; Gray JE
    J Thorac Dis; 2018 Feb; 10(Suppl 3):S433-S450. PubMed ID: 29593889
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.
    Poon E; Mullins S; Watkins A; Williams GS; Koopmann JO; Di Genova G; Cumberbatch M; Veldman-Jones M; Grosskurth SE; Sah V; Schuller A; Reimer C; Dovedi SJ; Smith PD; Stewart R; Wilkinson RW
    J Immunother Cancer; 2017 Aug; 5(1):63. PubMed ID: 28807001
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
    Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
    Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
    Hu ZI; Ho AY; McArthur HL
    Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.